SuperworthCorMedix EPS CRMD
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- $2.13
- Latest quarter, Q2 FY26
- $0.29
- +4% on a year earlier
- Fiscal year 2025
- $1.99
CorMedix's earnings per share was $2.13 over the twelve months to Jun 30, 2026, up 184% on a year earlier.
In its latest quarter, Q2 FY26, it was $0.29, up 4% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $1.99 | n/a |
| FY2024 | −$0.33 | n/a |
| FY2023 | −$0.92 | n/a |
| FY2022 | −$0.74 | n/a |
| FY2021 | −$0.74 | n/a |
| FY2020 | −$1.74 | n/a |
| FY2019 | −$1.81 | n/a |
| FY2017 | −$3.05 | n/a |
| FY2016 | −$3.15 | n/a |
| FY2015 | −$3.05 | n/a |
| FY2014 | −$6.25 | n/a |
| FY2013 | −$3.50 | n/a |
| FY2012 | −$1.45 | n/a |
| FY2011 | −$2.95 | n/a |
| FY2010 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.29 | +4% | $2.13 | |
| Q1 FY26 | $0.43 | +43% | $2.12 | |
| Q4 FY25 | $0.15 | −32% | $1.99 | |
| Q3 FY25 | $1.26 | n/a | $2.06 | |
| Q2 FY25 | $0.28 | n/a | $0.75 | |
| Q1 FY25 | $0.30 | n/a | $0.22 | |
| Q4 FY24 | $0.22 | n/a | −$0.33 | |
| Q3 FY24 | −$0.05 | n/a | −$0.81 | |
| Q2 FY24 | −$0.25 | n/a | −$0.93 | |
| Q1 FY24 | −$0.25 | n/a | −$0.93 | |
| Q4 FY23 | −$0.26 | n/a | −$0.92 | |
| Q3 FY23 | −$0.17 | n/a | −$0.86 |
Against its peers
Companies in Drug Manufacturers - General nearest CorMedix's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| CRMDCorMedix | $2.13 | +184% a year |
| ZVRAZevra Therapeutics | $0.93 | |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| ARVNArvinas | $0.16 | |
| ABUSArbutus Biopharma | $0.78 | |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| OMEROmeros | $1.52 | |
| PCRXPacira BioSciences | $0.35 | |
| ANABAnaptysbio | $4.57 | |
| Peer median | $0.85 |
Where CorMedix ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on CorMedix
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.